BioNTech to Expand Oncology Clinical Pipeline and Pivot Business

BNTX BioNTech SE ADR

$92.06 -3.35%

View chart & analysis →

1. 1BioNTech is conducting more than 25 Phase 2 and Phase 3 oncology trials.
2. 2The company plans to reach its goal of 15 Phase 3 clinical trials by the end of 2026.
3. 3At least 17 late-stage data results from BioNTech are expected through 2030 and beyond.

Source Nasdaq +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →